Pfizer Inc. Continues Development Program for RemoxyĀ® (oxycodone … –…

Pfizer Inc. (NYSE: PFE) announced today that having achieved technical milestones related to manufacturing it will continue the development program for Remoxy® (oxycodone) Extended-Release Capsules CII. Following guidance received from the U.S. Food and Drug Administration (FDA) earlier this year Pfizer will proceed with the additional clinical studies and other actions required to address the Complete Response Letter received in June (more…)

Vertex’s Data from Phase 2 VX-809 Study Supports Plan for Program in Early … – Proactive…

Below is a look at some of the headlines for companies that made news in the healthcare sector on October 11, 2012.

Incorporated (Nasdaq: VRTX)
 announced data from a Phase 2 study of VX-809 combined with ivacaftor in people with the most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, F508del, will be presented by lead study investigator Michael P. (more…)

How Drug Dealers Might Have Targeted Walgreens Supply Chain – Wall Street Journal (blog)

Walgreens CIO Tim Theriault says the illegal diversion of a large quantity of painkillers from a company distribution center in Florida was not the result of a technology breakdown or glitch.

The Drug Enforcement Agency on Sept. 14 shut down shipments of oxycodone, a controlled substance, at a Walgreens facility in Florida after detecting suspiciously high sales of the pain-killer at a (more…)